Financing ·
Nexalin Technology entered into a Securities Purchase Agreement to issue and sell 2,419,355 shares of common stock at…
NXLIWNexalin Technology, Inc.
Nexalin Technology entered into a Securities Purchase Agreement to issue and sell 2,419,355 shares of common stock at $0.31 per share in a registered direct offering, generating approximately $750,000 in gross proceeds. Concurrently, the company issued warrants to purchase up to 1,209,677 shares at an exercise price of $0.50 per share. The company also executed an Any Market Purchase Agreement with Alumni Capital LP, providing access to up to $15 million in capital through future purchases, subject to a $300,000 commitment fee payable in cash or equity. Maxim Group LLC served as the financial advisor for a $100,000 fee. The registered offering is expected to close on August 20, 2026. Nexalin Technology operates in the medical device industry, developing neuromodulation therapies for chronic pain management.